Eli Lilly Canada Inc v Mylan Pharmaceuticals ULC

Counsel to Mylan in successfully defending multiple related NOC proceedings and appeals relating to patents over CIALIS® (tadalafil), the first generic challenge to CIALIS®. Mylan successfully justified allegations of invalidity and non-infringement in respect of a dosage patent and a formulation patent, allowing Mylan to enter the market four years earlier than it would have otherwise. Lilly abandoned its appeal of the decision on the dosage patent, and the Federal Court of Appeal upheld the decision on the formulation patent. (Prior to joining Lenczner Slaght)